Minority Shareholder of Enzychem Lifesciences Solicits Proxies to Oppose Executive Officer System and Real Estate Business Addition at EGM
Shareholder Nam Yun-hee, holding a 0.30% stake, is soliciting proxies to oppose the proposed amendments to the articles of incorporation at Enzychem Lifesciences' first extraordinary general meeting of 2026.
The introduction of a representative executive officer system may blur management accountability and weaken board oversight, while adding new business purposes unrelated to the core biotech business such as land acquisition and modular housing could reduce capital allocation efficiency.
The solicitor requests shareholders to vote only against the articles amendment items, without expressing an opinion on the director election agenda.
The company has a history of significant management crises including trading suspension due to internal control deficiencies and accounting irregularities, posing additional governance risks.
[AI Summary]Enzychem Lifesciences faces a proxy contest from a minority shareholder opposing governance changes. The proposed executive officer system and real estate business additions could dilute shareholder rights and divert focus from core operations, negatively impacting stock value. Combined with past governance failures, uncertainty is elevated.